Zürcher Nachrichten - EU watchdog approves vaccine targeting Omicron sub-variants

EUR -
AED 3.829636
AFN 73.124732
ALL 98.67132
AMD 416.19609
ANG 1.876087
AOA 950.891327
ARS 1069.345538
AUD 1.669845
AWG 1.876758
AZN 1.770715
BAM 1.958605
BBD 2.10181
BDT 124.398167
BGN 1.960374
BHD 0.392863
BIF 3078.208714
BMD 1.042643
BND 1.414526
BOB 7.193302
BRL 6.648516
BSD 1.040991
BTN 88.60991
BWP 14.457707
BYN 3.406679
BYR 20435.808856
BZD 2.0947
CAD 1.495203
CDF 2992.386179
CHF 0.922649
CLF 0.037382
CLP 1031.476921
CNY 7.610041
CNH 7.617776
COP 4580.707408
CRC 528.557017
CUC 1.042643
CUP 27.630048
CVE 110.423152
CZK 25.205537
DJF 185.375501
DKK 7.478911
DOP 63.410819
DZD 140.801661
EGP 52.92566
ERN 15.63965
ETB 132.542832
FJD 2.417525
FKP 0.825755
GBP 0.816351
GEL 2.930018
GGP 0.825755
GHS 15.301916
GIP 0.825755
GMD 75.070186
GNF 8996.885643
GTQ 8.018484
GYD 217.791929
HKD 8.098935
HNL 26.448881
HRK 7.478782
HTG 136.114948
HUF 412.147024
IDR 16871.115647
ILS 3.805893
IMP 0.825755
INR 89.039628
IQD 1363.65307
IRR 43882.250586
ISK 145.500487
JEP 0.825755
JMD 162.192297
JOD 0.739546
JPY 164.034903
KES 134.54284
KGS 90.71006
KHR 4183.992455
KMF 486.002152
KPW 938.378395
KRW 1518.722356
KWD 0.321322
KYD 0.867543
KZT 539.282378
LAK 22765.605669
LBP 93219.612277
LKR 306.799408
LRD 189.461353
LSL 19.356323
LTL 3.078655
LVL 0.630685
LYD 5.110319
MAD 10.497735
MDL 19.206508
MGA 4910.032314
MKD 61.618252
MMK 3386.464796
MNT 3542.901828
MOP 8.327727
MRU 41.555517
MUR 49.077589
MVR 16.043304
MWK 1805.085304
MXN 21.04758
MYR 4.678368
MZN 66.628796
NAD 19.356323
NGN 1606.880003
NIO 38.304862
NOK 11.83908
NPR 141.776056
NZD 1.846972
OMR 0.400904
PAB 1.040991
PEN 3.876352
PGK 4.225051
PHP 61.161205
PKR 289.808373
PLN 4.26867
PYG 8118.627773
QAR 3.786022
RON 4.988317
RSD 117.316157
RUB 104.099332
RWF 1452.179861
SAR 3.908442
SBD 8.741058
SCR 14.86499
SDG 627.15075
SEK 11.552884
SGD 1.408089
SHP 0.825755
SLE 23.773767
SLL 21863.712025
SOS 594.952111
SRD 36.553015
STD 21580.611407
SVC 9.109046
SYP 2619.672847
SZL 19.364735
THB 35.595791
TJS 11.388311
TMT 3.659678
TND 3.319254
TOP 2.441975
TRY 36.689711
TTD 7.074132
TWD 34.104442
TZS 2523.805691
UAH 43.648315
UGX 3810.457466
USD 1.042643
UYU 46.336365
UZS 13439.248145
VES 53.775216
VND 26514.419347
VUV 123.784702
WST 2.880602
XAF 656.897831
XAG 0.035236
XAU 0.000398
XCD 2.817795
XDR 0.798143
XOF 656.897831
XPF 119.331742
YER 261.051846
ZAR 19.454087
ZMK 9385.039032
ZMW 28.809262
ZWL 335.73072
  • NGG

    -0.1600

    58.86

    -0.27%

  • SCS

    0.0800

    11.73

    +0.68%

  • GSK

    -0.0300

    34.03

    -0.09%

  • AZN

    -0.3300

    66.3

    -0.5%

  • BP

    0.0400

    28.79

    +0.14%

  • BTI

    0.0400

    36.26

    +0.11%

  • RIO

    -0.0300

    59.2

    -0.05%

  • RBGPF

    59.8000

    59.8

    +100%

  • CMSD

    0.1000

    23.65

    +0.42%

  • CMSC

    -0.1321

    23.77

    -0.56%

  • BCE

    0.0600

    22.9

    +0.26%

  • BCC

    0.9500

    123.19

    +0.77%

  • RELX

    0.3000

    45.89

    +0.65%

  • VOD

    0.0600

    8.43

    +0.71%

  • RYCEF

    -0.0100

    7.24

    -0.14%

  • JRI

    0.0500

    12.15

    +0.41%

EU watchdog approves vaccine targeting Omicron sub-variants
EU watchdog approves vaccine targeting Omicron sub-variants / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP

EU watchdog approves vaccine targeting Omicron sub-variants

The EU's medicines watchdog on Monday approved a vaccine specifically targeting the new and contagious types of the Omicron variant amid fears of a new wave of Covid-19 winter infections.

Text size:

The so-called "bivalent" jab, made by Pfizer/BioNTech, is directed at the highly infectious BA.4 and BA.5 types of the variant and is the first of its kind to be approved within the 27-nation bloc.

"This recommendation will further extend the arsenal of available vaccines to protect people against Covid-19 as the pandemic continues and new waves of infections are anticipated in the cold season," the European Medicines Agency (EMA) said.

The vaccine also targets "the original strain of SARS-CoV-2" and comes 11 days after the Amsterdam-based drug watchdog approved vaccines by Pfizer and Moderna against the Omicron BA.1 variant.

The latest shot is aimed at people over 12 and who have already received at least one primary vaccination against the coronavirus, and it is an adaptive version of Pfizer's original Comirnaty vaccine.

European nations have been keen to rush through the new generation of jabs so they can start booster campaigns ahead of a feared Covid surge in the latter part of this year.

The latest vaccines "better match the circulating variants of SARS-CoV-2 and are expected to provide broader protection against different variants," the EMA said.

"Prompt assessment of the available data on these adapted vaccines will enable their timely deployment in the autumn vaccination campaigns," it added.

The EMA's recommendation -- which will now be sent to the European Commission for a final decision -- was specifically based on clinical data from Pfizer's vaccines aimed at the original virus and the Omicron BA.1 variant.

- New wave feared -

"Apart from containing mRNA matching different, but closely related, Omicron sub-variants, Comirnaty Original/Omicron BA.4-5 and Comirnaty Original/Omicron BA.1 have the same composition," the EMA said.

Pfizer's vaccine works on the principle of tiny molecules carrying instructions for the human body to temporarily produce spike proteins similar to those found on the coronavirus -- and which it uses to enter the body's cells.

The body's immune system recognises the spike protein as foreign and activates natural defences against them.

When a person then comes in contact with the real virus, the body's immune system will also recognise and attack it.

The United States authorised its first anti-Omicron vaccines late last month, approving Pfizer and Moderna jabs for the BA.4 and BA.5 strains.

Britain authorised the Moderna vaccine for the BA.1 type in mid-August.

While the original vaccines, approved nearly two years ago provided some protection against newer coronavirus variants, the race had been on to come out with a newer group of vaccines that also target the milder but more infectious Omicron strains.

While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sub-lineages have dominated throughout 2022.

The BA.4 and BA.5 types have in particular helped to drive a wave of new cases of the disease in Europe and the United States in recent months.

All Omicron variants tend to have a milder disease course as they settle less in the lungs and more in the upper nasal passages, causing symptoms like fever, tiredness and loss of smell.

jhe/rox

O.Hofer--NZN